Lipocine Inc. — Director's Dealing 2017

Jan 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2017-01-26

Reporting Person: HILL STEPHEN A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-26	Restricted Stock Unit	$0	A	10000	Acquired	2027-01-25	Common Stock (10000)	Direct

Footnotes

F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit

F2: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.